Cancer drug holds promise for shrinking polycystic kidney cy

Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease, can lead to kidney enlargement and eventual loss of function.

Related Keywords

Bogdan Fedeles , Sakunchai Khumsubdee , Robert Croy , Stefan Somlo , Betsyp Leitch , Sorin Fedeles , Jake Campolo , John Essigmann , Sallys Liu , Denise Andrade , Yale University School Of Medicine , National Institute Of Environmental Health Sciences , Environmental Health Sciences , Proceedings Of The National Academy Sciences , Polycystic Kidney Disease Outcomes Consortium , Us Department Of Defense , Massachusetts Institute Of Technology , Research Scientist Nina Gubina , National Institutes Of Health , Yale University School , National Academy , Biological Engineering , Long Professor , National Institutes , National Institute , Kidney , Autosomal , Autosomal Dominant Polycystic Kidney Disease , Dancer , Cancer Treatment , Compound , Cyst , Dialysis , Na , Free Radicals , Kidney Cyst , Kidney Disease , Kidney Transplant , Edicine , Metabolism , Itochondria , Oxidative Stress , Polycystic Kidney Disease , Esearch , Stress , Olvaptan , Transplant , Humor ,